A case report of occurrence of severe alopecia areata as post-COVID-19 complication
Post-COVID Alopecia Areata
DOI:
https://doi.org/10.66344/jpad.33.4.2023.2301Keywords:
post-Covid, Alopecia Areata, hyperactive immunity, TreatmentAbstract
COVID-19 has been markedly affecting the lives of individuals in various ways from past two years. Post COVID-19 complications are among those which have rendered patients more vulnerable to secondary diseases. Hyperactive immune system is one of the post-COVID complications. This has led to emergence of all forms of alopecia in patients who suffered from COVID-19. A 33-year-old female is experiencing severe alopecia areata as a post-COVID complication with aberrant response towards treatments from past 9 months. Topical minoxidil 5% and tacrolimus 0.1% along with scalp platelets-rich-plasma (PRP) with micro-needling has been proven successful in regrowth after two months of treatment. Although reoccurrence of few bald patches has been observed.References
L.N. Schwartzberg, S. Advani, D.C. Clancy, A. Lin, J.L. Jorizzo A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis
Lee, H. H., Gwillim, E., Patel, K. R., Hua, T., Rastogi, S., Ibler, E., & Silverberg, J. I. (2020). Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 82(3), 675–682. https://doi.org/10.1016/j.jaad.2019.08.032
Kutlu Ö, AktaÅŸ H, Ä°mren IG, et al. Shortâ€term stressâ€related increasing cases of alopecia areata during the COVIDâ€19 pandemic. J Dermatolog Treat 2020; 19: 1.
Aşkın, Ö., Özkoca, D., Uzunçakmak, T. K., & Serdaroğlu, S. (2021). Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatologic therapy, 34(2), e14746. https://doi.org/10.1111/dth.14746
Seirafianpour, F., Sodagar, S., Pour Mohammad, A., Panahi, P., Mozafarpoor, S., Almasi, S., & Goodarzi, A. (2020). Cutaneous manifestations and considerations in COVIDâ€19 pandemic: a systematic review. Dermatologic therapy, 33(6), e13986.
Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., Alessandrini, A., Calvieri, S., Caro, G., D'arino, A., Federico, A., Magri, F., Pigliacelli, F., Amendolagine, G., Annunziata, M. C., Arisi, M. C., Astorino, S., Babino, G., Bardazzi, F., Barruscotti, S., … Fortuna, M. C. (2019). Italian Guidelines in diagnosis and treatment of alopecia areata. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, 154(6), 609–623. https://doi.org/10.23736/S0392-0488.19.06458-7
Chrousos G. P. (1995). The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. The New England journal of medicine, 332(20), 1351–1362. https://doi.org/10.1056/NEJM199505183322008
Azzawi S, Penzi L, R, Senna M, M: Immune Privilege Collapse and Alopecia Development: Is Stress a Factor. Skin Appendage Disord 2018;4:236-244. doi: 10.1159/000485080
Freire, P C B; Petri, V; Atallah, A N (2019). Minoxidil for Patchy Alopecia Areata: Systematic Review and Meta-Analysis. Journal of the European Academy of Dermatology and Venereology, (), –. doi:10.1111/jdv.15545
Hind M. Almohanna, Azhar A. Ahmed, Jacob W. Griggs, Antonella Tosti, Platelet-Rich Plasma in the Treatment of Alopecia Areata: A Review, Journal of Investigative Dermatology Symposium Proceedings, Volume 20, Issue 1, 2020, Pages S45-S49, ISSN 1087-0024, https://doi.org/10.1016/j.jisp.2020.05.002.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
